Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.

White RJ, Vonk-Noordegraaf A, Rosenkranz S, Oudiz RJ, McLaughlin VV, Hoeper MM, Grünig E, Ghofrani HA, Chakinala MM, Barberà JA, Blair C, Langley J, Frost AE.

Respir Res. 2019 Sep 12;20(1):208. doi: 10.1186/s12931-019-1180-1.

2.

Barriers to physical activity in patients with pulmonary hypertension.

Cascino TM, McLaughlin VV, Richardson CR, Behbahani-Nejad N, Moles VM, Visovatti SH, Jackson EA.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019847895. doi: 10.1177/2045894019847895.

3.

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.

Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF.

Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.

4.

An insider view on the World Symposium on Pulmonary Hypertension.

Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Lancet Respir Med. 2019 Jun;7(6):484-485. doi: 10.1016/S2213-2600(19)30111-0. Epub 2019 Apr 4. No abstract available.

PMID:
30956061
5.

Physical activity and quality of life in patients with pulmonary hypertension.

Cascino TM, McLaughlin VV, Richardson CR, Behbahani-Nejad N, Moles VM, Visovatti SH, Jackson EA.

Eur Respir J. 2019 Jun 20;53(6). pii: 1900028. doi: 10.1183/13993003.00028-2019. Print 2019 Jun. No abstract available.

PMID:
30880287
6.

EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH.

Benza R, Corris P, Ghofrani A, Kanwar MK, McLaughlin VV, Raina A, Simonneau G.

Pulm Circ. 2019 Feb 26:2045894019837849. doi: 10.1177/2045894019837849. [Epub ahead of print] No abstract available.

PMID:
30803329
7.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

8.

An overview of the 6th World Symposium on Pulmonary Hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir J. 2019 Jan 24;53(1). pii: 1802148. doi: 10.1183/13993003.02148-2018. Print 2019 Jan. No abstract available.

9.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

10.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

11.

Pulmonary Hypertension in Women.

Franco V, Ryan JJ, McLaughlin VV.

Heart Fail Clin. 2019 Jan;15(1):137-145. doi: 10.1016/j.hfc.2018.08.013. Epub 2018 Oct 24. Review.

PMID:
30449376
12.

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.

Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB.

Chest. 2018 Oct;154(4):848-861. doi: 10.1016/j.chest.2018.04.027. Epub 2018 Apr 26.

13.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

14.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

15.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

16.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
17.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
18.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

19.

Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension.

Bhave NM, Visovatti SH, Kulick B, Kolias TJ, McLaughlin VV.

Int J Cardiovasc Imaging. 2017 Jun;33(6):847-855. doi: 10.1007/s10554-017-1081-7. Epub 2017 Feb 6.

20.

Usefulness of Echocardiography/Doppler to Reliably Predict Elevated Left Ventricular End-Diastolic Pressure in Patients With Pulmonary Hypertension.

Cameron DM, McLaughlin VV, Rubenfire M, Visovatti S, Bach DS.

Am J Cardiol. 2017 Mar 1;119(5):790-794. doi: 10.1016/j.amjcard.2016.11.016. Epub 2016 Dec 2.

PMID:
28040189
21.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

22.

Safety of regadenoson stress testing in patients with pulmonary hypertension.

Moles VM, Cascino T, Saleh A, Mikhova K, Lazarus JJ, Ghannam M, Yun HJ, Konerman M, Weinberg RL, Ficaro EP, Corbett JR, McLaughlin VV, Murthy VL.

J Nucl Cardiol. 2018 Jun;25(3):820-827. doi: 10.1007/s12350-016-0734-6. Epub 2016 Nov 28.

PMID:
27896702
23.

Beast of Pulmonary Arterial Hypertension Burden.

Mathai SC, McLaughlin VV.

JAMA Cardiol. 2016 Dec 1;1(9):1030-1031. doi: 10.1001/jamacardio.2016.3829. No abstract available.

PMID:
27851836
24.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
25.

Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel.

Sista AK, Goldhaber SZ, Vedantham S, Kline JA, Kuo WT, Kahn SR, Kabrhel C, McLaughlin VV, White SB, Kim NH, Gray M, Simon MA, Benenati JF, Misra S, Sterling KM, Kee ST, Konstantinides SV, Jaff MR, Kearon C.

J Vasc Interv Radiol. 2016 Jun;27(6):787-94. doi: 10.1016/j.jvir.2016.03.035. Epub 2016 Jun 3. No abstract available.

PMID:
27287967
26.

Treatment of pulmonary hypertension.

Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Galiè N.

Lancet Respir Med. 2016 Apr;4(4):323-36. doi: 10.1016/S2213-2600(15)00542-1. Epub 2016 Mar 12. Review.

PMID:
26975811
27.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

28.

Improving patient outcomes in pulmonary hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir Rev. 2015 Dec;24(138):550-1. doi: 10.1183/16000617.0064-2015. No abstract available.

29.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

30.

Management of pulmonary arterial hypertension.

McLaughlin VV, Shah SJ, Souza R, Humbert M.

J Am Coll Cardiol. 2015 May 12;65(18):1976-97. doi: 10.1016/j.jacc.2015.03.540. Review.

31.

[Treatment goals of pulmonary hypertension].

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:95-105. Turkish.

32.

[Updated treatment algorithm of pulmonary arterial hypertension].

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:78-94. Turkish.

33.

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.

Visovatti SH, Distler O, Coghlan JG, Denton CP, Grünig E, Bonderman D, Müller-Ladner U, Pope JE, Vonk MC, Seibold JR, Torres-Martin JV, Doelberg M, Chadha-Boreham H, Rosenberg DM, McLaughlin VV, Khanna D.

Arthritis Res Ther. 2014 Dec 10;16(6):493. doi: 10.1186/s13075-014-0493-1.

34.

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study.

Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW.

Chest. 2015 Feb;147(2):484-494. doi: 10.1378/chest.14-1004.

35.

Treatment goals of pulmonary hypertension.

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D73-81. doi: 10.1016/j.jacc.2013.10.034. Review.

36.

Updated treatment algorithm of pulmonary arterial hypertension.

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-72. doi: 10.1016/j.jacc.2013.10.031. Review.

37.

Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.

Khanna D, Tan M, Furst DE, Hill NS, McLaughlin VV, Silver RM, Steen VD, Langer A, Seibold JR; QuERI-SSc Investigators.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-21-7. Epub 2013 Dec 2.

PMID:
24295227
38.

Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.

McLaughlin VV, Palevsky HI.

Clin Chest Med. 2013 Dec;34(4):825-40. doi: 10.1016/j.ccm.2013.09.003. Epub 2013 Oct 18. Review.

PMID:
24267307
39.

Pulmonary hypertension: types and treatments.

Rose-Jones LJ, Mclaughlin VV.

Curr Cardiol Rev. 2015;11(1):73-9. Review.

40.

Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.

Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV; Scleroderma Foundation and Pulmonary Hypertension Association.

Arthritis Rheum. 2013 Dec;65(12):3194-201. doi: 10.1002/art.38172.

41.

One-year experience with intravenous treprostinil for pulmonary arterial hypertension.

Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.

J Heart Lung Transplant. 2013 Sep;32(9):889-96. doi: 10.1016/j.healun.2013.06.008.

PMID:
23953817
42.

Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.

Rubenfire M, Huffman MD, Krishnan S, Seibold JR, Schiopu E, McLaughlin VV.

Chest. 2013 Oct;144(4):1282-1290. doi: 10.1378/chest.12-0653.

PMID:
23744060
43.

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR; DETECT study group.

Ann Rheum Dis. 2014 Jul;73(7):1340-9. doi: 10.1136/annrheumdis-2013-203301. Epub 2013 May 18.

44.

Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study.

Deaño RC, Glassner-Kolmin C, Rubenfire M, Frost A, Visovatti S, McLaughlin VV, Gomberg-Maitland M.

JAMA Intern Med. 2013 May 27;173(10):887-93. doi: 10.1001/jamainternmed.2013.319.

PMID:
23568223
45.

Has the 6-min walk distance run its course?

McLaughlin VV.

Chest. 2012 Dec;142(6):1363-1365. doi: 10.1378/chest.12-1110. No abstract available.

PMID:
23208324
46.

Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey.

Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, Preston IR, Barberà JA, Hassoun PM, Halank M, Jaïs X, Nickel N, Hoeper MM, Humbert M.

Eur Respir J. 2013 Jun;41(6):1302-7. doi: 10.1183/09031936.00089212. Epub 2012 Nov 8.

47.

Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap.

McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ; Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI) Investigators.

Chest. 2013 Feb 1;143(2):324-332. doi: 10.1378/chest.11-3060.

PMID:
22910999
48.

Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension.

Visovatti SH, Hyman MC, Bouis D, Neubig R, McLaughlin VV, Pinsky DJ.

PLoS One. 2012;7(7):e40829. doi: 10.1371/journal.pone.0040829. Epub 2012 Jul 11.

49.

Modern age pathology of pulmonary arterial hypertension.

Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM.

Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72. doi: 10.1164/rccm.201201-0164OC. Epub 2012 Jun 7.

50.

Looking to the future: a new decade of pulmonary arterial hypertension therapy.

McLaughlin VV.

Eur Respir Rev. 2011 Dec;20(122):262-9. doi: 10.1183/09059180.00006411. Review.

Supplemental Content

Loading ...
Support Center